NextCure, Inc. (NXTC)
- Previous Close
0.4133 - Open
0.4305 - Bid 0.3066 x 200
- Ask 0.5677 x 200
- Day's Range
0.4205 - 0.4499 - 52 Week Range
0.2240 - 1.8200 - Volume
55,628 - Avg. Volume
154,985 - Market Cap (intraday)
12.286M - Beta (5Y Monthly) 1.04
- PE Ratio (TTM)
-- - EPS (TTM)
-1.7700 - Earnings Date Jul 30, 2025 - Aug 4, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.00
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
www.nextcure.comRecent News: NXTC
View MorePerformance Overview: NXTC
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NXTC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NXTC
View MoreValuation Measures
Market Cap
12.29M
Enterprise Value
-38.66M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.22
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-36.39%
Return on Equity (ttm)
-63.94%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-49.52M
Diluted EPS (ttm)
-1.7700
Balance Sheet and Cash Flow
Total Cash (mrq)
55.86M
Total Debt/Equity (mrq)
10.46%
Levered Free Cash Flow (ttm)
-25.45M